drugset / Trial / NCT01311674

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

NCT01311674

Phase 3 Terminated 141 enrolled Emergent BioSolutions
RandomizedParallel-groupOpen-labelOther

Summary

Hepatitis B Virus Antibody Booster Program

Timeline

Start
2009-09
Primary completion
2011-03-11
Completion
2011-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine 20 ug
Subject Hepatitis B vaccine Vaccine 40 ug

Indications

No indication recorded.